Updated Equine Influenza Vaccine

An updated equine influenza vaccine (inactivated) was developed by NRCE, utilizing recent EI epizootic isolate. For this purpose, EIV’s isolated from Katra (Jammu), Mysore (Karnataka), Ahmedabad (Gujarat) and Gopeshwar (Uttarakhand) were characterized by sequence analysis of HA gene for selecting the virus for updation of the vaccine. The sequence analysis classified the viruses to the clade 2 of Florida sublineage of American lineage. The EIV isolate-A/eq/Katra (Jammu)/06/08 (H3N8) was selected for updating the vaccine. The inactivated virus was checked for the sterility and inactivation prior to vaccine production. The HA content of the virus was quantified and adjusted to 20 µg/dose. The vaccine was tested for potency in the Guinea pigs followed by safety and potency testing in the equines. None of the horses showed any untoward reaction. The animals were given booster dose of the vaccine after four weeks of first vaccination. Isotype-ELISA was used to measure post vaccine isotype kinematics. The updated vaccine generated primarily IgGa, followed by IgGb and IgT that was observed two week post-vaccination which persisted for more than 8 weeks post-vaccination period. The dosage of the vaccine is 1ml (I/M) for animals above six months of age with booster at 4 weeks after first dose. Vaccination should be repeated annually

Updated Equine Influenza Vaccine